SCHEMBL1858372

SCHEMBL1858372

COC(=O)C(C)CCN1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
ALDH1A1 P00352 3/20 0.41
POLB P06746 1/20 0.41
ATM Q13315 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GLA P06280 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TP53 P04637 1/20 0.39
THRB P10828 1/20 0.39
HTT P42858 1/20 0.39
ALOX15 P16050 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP1A2 P05177 1/20 0.39
MAPK1 P28482 1/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1852962 0.98 ATM (0.40) MAPTALDH1A1POLBATMKDM4E
SCHEMBL8633836 0.87 MAPT (0.42) MAPTALDH1A1POLBATMKDM4E
SCHEMBL8630761 0.85 MAPT (0.39) MAPTALDH1A1POLBATMKDM4E
SCHEMBL1857702 0.84 CYP3A4 (0.42) MAPTALDH1A1POLBKDM4EL3MBTL1
SCHEMBL12447226 0.83 KDM4E (0.37) MAPTALDH1A1POLBKDM4ENPSR1
SCHEMBL12447234 0.83 TDP1 (0.48) ALDH1A1GLASMN1; SMN2
SCHEMBL1863187 0.82 CYP3A4 (0.43) MAPTALDH1A1POLBKDM4EL3MBTL1
SCHEMBL9774559 0.81 CHRM2 (0.49) MAPTALDH1A1POLBALOX15MEN1
SCHEMBL12447227 0.81 ALDH1A1 (0.38) MAPTALDH1A1POLBKDM4ETP53
SCHEMBL2444748 0.81 MAPT (0.43) MAPTALDH1A1POLBKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323988-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS Wyeth LLC (US) 2011-05-25 EP disclosed
US-20100130474-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS WYETH (US) 2010-05-27 US disclosed
WO-2010009290-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS WYETH (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130474-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS CHRNA7, CHRNA6, CHRNA2 MAPT 501/4885ALDH1A1 2163/4885POLB 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.